Trial Profile
A Prospective, Single-Arm, Multicenter, Pragmatic Phase-IV Trial Investigating Safety and Effectiveness of DARZALEX (Daratumumab) In Indian Subjects With Relapsed and Refractory Multiple Myeloma, Whose Prior Therapy Included a Proteasome Inhibitor and an Immunomodulatory Agent
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Aug 2022
Price :
$35
*
At a glance
- Drugs Daratumumab (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Johnson & Johnson
- 15 Aug 2022 Status changed from active, no longer recruiting to completed.
- 24 Mar 2022 Planned End Date changed from 30 Aug 2022 to 25 Jul 2022.
- 24 Mar 2022 Planned primary completion date changed from 31 Jan 2022 to 25 Jul 2022.